Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Net Cash Flow: 2014-2025

Historic Net Cash Flow for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to -$107.2 million.

  • Theravance Biopharma's Net Cash Flow fell 366.56% to -$107.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.4 million, marking a year-over-year increase of 413.40%. This contributed to the annual value of -$1.7 million for FY2024, which is 99.32% up from last year.
  • Per Theravance Biopharma's latest filing, its Net Cash Flow stood at -$107.2 million for Q3 2025, which was down 162.55% from $171.3 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Net Cash Flow ranged from a high of $331.2 million in Q3 2022 and a low of -$120.4 million during Q4 2022.
  • For the 3-year period, Theravance Biopharma's Net Cash Flow averaged around -$11.2 million, with its median value being -$23.0 million (2024).
  • As far as peak fluctuations go, Theravance Biopharma's Net Cash Flow slumped by 3,014.21% in 2023, and later spiked by 2,387.22% in 2025.
  • Over the past 5 years, Theravance Biopharma's Net Cash Flow (Quarterly) stood at -$34.3 million in 2021, then crashed by 251.16% to -$120.4 million in 2022, then surged by 73.30% to -$32.1 million in 2023, then skyrocketed by 144.86% to $14.4 million in 2024, then slumped by 366.56% to -$107.2 million in 2025.
  • Its last three reported values are -$107.2 million in Q3 2025, $171.3 million for Q2 2025, and $72.8 million during Q1 2025.